Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Monday, Sanofi Said Results From GEMINI 1 And 2 Phase 3 Studies Of Tolebrutinib Did Not Meet The Primary Endpoint Of Reducing Annualized Relapse Rate, Compared To Teriflunomide, In Relapsing Forms Of Multiple Sclerosis

Author: Benzinga Newsdesk | September 03, 2024 03:47am

Posted In: SNY